332 results on '"Lindemann, K"'
Search Results
2. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
3. Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome – A single center retrospective analysis
4. Cognitive impairment in cervical cancer survivors—Exploring the discrepancy between subjective and objective assessment
5. VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
6. When to stop futile treatment towards end of life in gynaecological cancer patients: a population-based study in oslo county, norway
7. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
8. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
9. 62 End of life (EOL) care in gynecological cancer patients – a population-based study in oslo county, norway
10. 589P Circulating tumour DNA as prognostic factor in endometrial cancer: Updated results from an international multicenter study
11. 573P Role of CA125 in patients included in the DESKTOP III/ENGOT-ov20 trial
12. 602P Using scenarios to explain survival times – attitudes of women with gynaecological cancer
13. 1437P Does subjective cognitive impairment reflect objective cognitive impairment in cervical cancer survivors?
14. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
15. First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
16. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
17. 1050 Pelvic exenteration for vulvar cancer: postoperative morbidity and oncologic outcome – a single center retrospective study
18. 241 Impact of co-medication on survival in patients with ovarian cancer – A analysis of 4 prospective trials of the AGO-OVAR and ENGOT/GCIG collaborators
19. 1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)
20. 1196 A randomised phase II study of combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. FANDANGO/ENGOT-EN1/FANDANGO
21. 405 Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
22. 751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group
23. LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
24. 740P Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
25. 792P Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
26. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
27. wpn2030 - Wissenschaftsplattform Nachhaltigkeit 2030. Wege zu einer nachhaltigen Arbeitswelt. Abschlussbericht der wpn2030-Arbeitsgruppe ‚Zukunft der Arbeit‘
28. A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC):NSGO-PALEO / ENGOT-EN3 trial
29. 428 Prospective evaluation of an ERAS pathway at a gynaecological oncology unit in oslo, norway
30. 414 Prognostic factors related to recurrence and survival of early stage vulvar squamous cell carcinoma
31. 5P Hormonal biomarkers can improve prediction of response to hormonal therapy in advanced and recurrent endometrial cancer: Results of the PROMOTE-R study
32. 871P Prevalence of self-reported cognitive impairment among cervical cancer survivors
33. LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
34. 881TiP A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer
35. Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
36. When to stop futile treatment towards end of life in gynaecological cancer patients: a population-based study in oslo county, norway
37. P30 FIGO stage 1B1 cervical cancer – an evaluation of a treatment strategy based on pelvic MRI and pelvic examination at oslo university hospital, norway
38. Step by step development of an electrochemical microanalytical system
39. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue
40. 62 End of life (EOL) care in gynecological cancer patients – a population-based study in oslo county, norway
41. Nasal Obstruction Symptom Evaluation Questionnaire and Age-Related Changes of the Nose
42. Kryptokokken-Meningoenzephalitis beim immunkompetenten Patienten imitiert eine tuberkulöse Meningitis mit Ventrikulitis und Hydrocephalus
43. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: Analysis of the AURELIA trial
44. Glückwunschadressen
45. Parental Unemployment and the Transition into Tertiary Education: Can Institutions Moderate the Adverse Effects?
46. Buchbesprechungen
47. Buchbesprechungen
48. Erfahrungen in der Konstruktion und Anwendung pneumatischer Lähmungsapparate: 1. Mitteilung
49. Kongenitale Formstörungen bei juvenilen Kyphosen
50. Über die Entstehung freier Körper im Talocruralgelenk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.